Volume 104, Issue 5 p. 890-899
Reviews

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Maciej J. Zamek-Gliszczynski

Corresponding Author

Maciej J. Zamek-Gliszczynski

Quantitative Drug Disposition, GlaxoSmithKline, King of Prussia, Pennsylvania, USA

Correspondence: Maciej J. Zamek-Gliszczynski ([email protected])Search for more papers by this author
Mitchell E. Taub

Mitchell E. Taub

Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim, Ridgefield, Connecticut, USA

Search for more papers by this author
Paresh P. Chothe

Paresh P. Chothe

Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Boston, Massachusetts, USA

Search for more papers by this author
Xiaoyan Chu

Xiaoyan Chu

Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Kenilworth, New Jersey, USA

Search for more papers by this author
Kathleen M. Giacomini

Kathleen M. Giacomini

Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, USA

Search for more papers by this author
Richard B. Kim

Richard B. Kim

Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada

Search for more papers by this author
Adrian S. Ray

Adrian S. Ray

Clinical Research, Gilead Sciences, Foster City, California, USA

Search for more papers by this author
Sophie L. Stocker

Sophie L. Stocker

Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, NSW, Australia & St Vincent's Clinical School, UNSW Sydney, NSW, Australia

Search for more papers by this author
Jashvant D. Unadkat

Jashvant D. Unadkat

Department of Pharmaceutics, University of Washington, Seattle, Washington, USA

Search for more papers by this author
Matthias B. Wittwer

Matthias B. Wittwer

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

Search for more papers by this author
Cindy Xia

Cindy Xia

Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International, Cambridge, Massachusetts, USA

Search for more papers by this author
Sook-Wah Yee

Sook-Wah Yee

Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, USA

Search for more papers by this author
Lei Zhang

Lei Zhang

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA

Search for more papers by this author
Yan Zhang

Yan Zhang

Drug Metabolism Pharmacokinetics & Clinical Pharmacology, Incyte, Wilmington, Delaware, USA

Search for more papers by this author
on behalf of the International Transporter Consortium

International Transporter Consortium

Search for more papers by this author
First published: 08 August 2018
Citations: 177

current affiliation: Adrian S. Ray Discovery Biology, Nimbus Therapeutics, Cambridge, Massachusetts, USA

Abstract

This white paper provides updated International Transporter Consortium (ITC) recommendations on transporters that are important in drug development following the 3rd ITC workshop. New additions include prospective evaluation of organic cation transporter 1 (OCT1) and retrospective evaluation of organic anion transporting polypeptide (OATP)2B1 because of their important roles in drug absorption, disposition, and effects. For the first time, the ITC underscores the importance of transporters involved in drug-induced vitamin deficiency (THTR2) and those involved in the disposition of biomarkers of organ function (OAT2 and bile acid transporters).

Conflict of interest

The authors declare no competing interests for this work.